Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Revvity Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $17.8, while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc pays a 0.25% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Revvity Inc is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| QYLD | RVTY | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $18.52 | $117.75 |
52-Week Low | $16.46 | $82.26 |
Market Cap | — | $12.33B |
Enterprise Value | — | $14.82B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $17.66, down 0.84% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with RSI at oversold levels. Recent dividend payments of $0.18-$0.19 highlight its income focus, though news articles question long-term wealth erosion versus Nasdaq growth.
The outlook remains cautious due to covered-call strategy limitations during market rallies. Risks include NAV erosion and underperformance versus benchmarks. Income-focused investors may find value, but growth-oriented investors face significant upside capture constraints in bullish markets.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
